サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179908

膠芽腫治療の世界市場-2023-2030

Global Glioblastoma Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
膠芽腫治療の世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

膠芽腫は、多形膠芽腫（GBM）としても知られています。膠芽腫は、脳や脊髄に発生する攻撃的なタイプのがんです。膠芽腫は、神経細胞を支えるアストロサイトと呼ばれる細胞から形成されます。膠芽腫は年齢に関係なく発生する可能性がありますが、高齢者に多く発生する傾向があります。治療には、放射線療法、化学療法、手術が含まれます。

市場力学

政府および非政府組織は、多形性膠芽腫に関する認識を高めるためにさまざまな取り組みを行っています。主要企業の強力な研究開発イニシアティブ、多形性膠芽腫の発生率の上昇、米国FDAによる新薬承認の増加が、予測期間中に市場を牽引する要因となっています。

世界中の政府や非政府機関が行うさまざまな取り組みを通じて、多形性膠芽腫を患う人々を教育することによる意識の向上が、市場成長の原動力になると予想されます。

モバイルメッセージングプラットフォームを提供するPing Mobileは、脳腫瘍に関する認知度を高めるためのモバイルキャンペーンを開始しました。これは、多形性膠芽腫に関する認知度を高め、多形性膠芽腫の研究活動のために寄付をするよう人々を動機付けるのに役立っています。さらに、全米脳腫瘍協会、カナダ脳腫瘍財団、Cure Brain Cancer Foundationなどの団体も、この疾患についての人々の認知度を高めるために多くの啓発活動を行っています。英国では、3月を「脳腫瘍啓発月間」として、脳腫瘍研究の会員慈善団体によって制定されたキャンペーンが行われています。このキャンペーンは、脳腫瘍の研究資金が不足していることを広く知ってもらい、脳腫瘍とその治療法について理解してもらうことを主な目的としています。また、ノボキュアは、脳腫瘍啓発月間に、多形性膠芽腫に関する啓発活動を行いました。これらの要因が、予測期間中の市場成長を促進しています。

多形性膠芽腫の治療に伴う高額な費用は、市場成長を阻害する大きな要因となっています。

商業保険に加入している患者が新たにTMZ治療を受けたGBMと診断された場合の直接医療費は相当なものであり、268,031ドルと推定されています。膠芽腫患者のケアに関連する直接費用を減少させるために、広範な研究が行われてきました。直接費用とは、関連するすべての治療や病気の管理に関連する費用など、病気に起因する費用で、保険の状況などの要因に応じて、（患者さんを含む）さまざまな関係者が負担する可能性があります。直接費用の大部分は治療開始後4ヶ月間に発生し、この疾患の生存率の低さを反映して、1年を超えると費用はプラトーとなります。放射線と手術は、GBMの直接費用に最も寄与しています。したがって、上記の要因から、予測期間において市場は阻害されることが予想されます。

COVID-19影響度分析

一般的にがん患者や膠芽腫患者は、重症急性呼吸器症候群コロナウイルス2型（SARS-CoV-2）の合併症を発症するリスクが高く、感染リスクと治療による臨床効果のバランスをとることが理想的です。この腫瘍群の攻撃的な挙動は、現在のパンデミック時の臨床判断を支援する集学的なチームの必要性を正当化するものです。固形がんの腫瘍形成におけるCOVID-19の役割は不明であり、神経膠腫の病態生理における役割も報告されていないです。グリア細胞や神経細胞は、その表面にACE2を発現していることが知られており、神経細胞はCOVID-19の感染ターゲットとなる可能性があります。

現在の高悪性度神経膠腫（HGG）治療ガイドラインは、無増悪生存期間と全生存期間（OS）を改善するためのエビデンスに基づくケアの枠組みを提供しています。パンデミックの間、医師は脆弱な集団におけるCOVID-19のリスクと、がん患者の治療不足のリスクとの間でバランスを取る必要があります。さらに、ヘルスケア従事者を保護し、患者への二次的なウイルス拡散を回避することが社会的なニーズとなっています。COVID-19のパンデミック時に膠芽腫患者にアプローチすることは、ほとんどの神経腫瘍センターで困難です。ブラジルの州によって医療格差が大きいため、医師が適切な治療方針を決定することが困難です。パフォーマンスステータスと分子プロファイルが良好な患者は、最も安全な切除と化学放射線療法の同時併用を含む標準治療プロトコルを受けるべきです。

高齢の患者やパフォーマンスステータスの悪い患者は慎重に扱うべきで、パフォーマンスステータスが良く、合併症のない患者がテモゾロミドによる低分割プロトコルで利益を得られない限り、COVID-19流行中は単剤療法レジメンが最も適していると思われます。現在の状況は、可能な限り最高のヘルスケアを提供するための新たな課題であり、患者との新しいコミュニケーション方法を見つけることが重要です。しかし、この状況は予測期間中に徐々に改善されると予想されます。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響因子
    • 促進要因
      • 世界中の政府や非政府機関が実施する様々な取り組みを通じて、多形性膠芽腫の患者を教育することによる認知度の向上が、市場成長の原動力になると予想されます。
    • 抑制要因
      • 多形性膠芽腫の治療に伴う高コストが、市場成長を阻害する主な要因となっています。
    • 市場機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • サプライチェーン
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 治療タイプ別

  • 化学療法
    • テモゾロミド
    • ベバシズマブ
    • カルムスチン
    • その他
  • 免疫療法
  • 電場療法
  • その他

第8章 分子タイプ別

  • 低分子化合物
  • 生物学的製剤

第9章 投与経路別

  • 経口
  • 非経口

第10章 エンドユーザー別

  • 病院
  • クリニック
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第13章 企業プロファイル

  • Genentech
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Amgen
  • Merck & Co., Inc
  • Teva Pharmaceutical Industries, Ltd.
  • Arbor Pharmaceuticals LLC
  • Sun Pharmaceutical Industries, Ltd.
  • F. Hoffman-La Roche
  • Novartis AG
  • Pfizer

第14章 世界の膠芽腫治療市場-DataM

目次
Product Code: DMPH3059

Market Overview

The global glioblastoma treatment market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Glioblastoma is also known as glioblastoma multiforme (GBM). Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells. Glioblastoma can occur at any age but tends to occur more often in older adults. Treatments include radiation, chemotherapy and surgery.

Market Dynamics

Governments and non-government bodies undertake various initiatives to raise awareness about glioblastoma multiforme. Strong R&D Initiatives from key players, rising incidence of glioblastoma multiforme and increasing US FDA approval of new drugs are the factors to drive the market in the forecast period.

Increasing awareness by educating people living with glioblastoma multiforme through various initiatives undertaken by governments and non-government bodies across the globe is expected to drive market growth.

Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps raise awareness about glioblastoma multiforme and motivates people to donate money for glioblastoma multiforme research activities. Moreover, organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The campaign's main aim is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Additionally, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month. These factors are driving the growth of the market in the forecast period.

The high cost associated with treating the glioblastoma multiforme is a major factor that hampers the market growth.

The direct medical costs of newly diagnosed TMZ-treated GBM in commercially insured patients are substantial, with estimated costs of $268,031. Extensive studies have been conducted to decrease the direct costs associated with care for patients with glioblastoma. Direct costs are those attributable to the disease, including all the associated therapies and costs associated with managing the disease, which may be borne by various parties (including the patient), depending on factors such as insurance status. The majority of direct costs were incurred in the first four months of treatment, with a plateau in costs beyond one year, reflecting the poor survival of this disease. Radiation and surgery contribute most to the direct costs of GBM. Thus, from the above factors, the market is expected to be hampered in the forecast period.

COVID-19 Impact Analysis

Cancer patients, in general, and glioblastoma patients, are at a higher risk of developing complications from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and striking a balance between the risk of infection and the clinical benefit of treatment is ideal. This group of tumors' aggressive behavior justifies the need for a multidisciplinary team to assist in clinical decisions during the current pandemic. COVID-19's role in the tumorigenesis of solid cancer is unknown, and its role in glioma pathophysiology has not been reported. Glial and neuronal cells are known to express ACE2 on their surfaces, making neuronal cells a potential target for COVID-19 infection.

The current high-grade glioma (HGG) treatment guidelines provide an evidence-based care framework to improve progression-free and overall survival (OS). During the pandemic, doctors must strike a balance between the risks of COVID-19 in a vulnerable population and the risk of under-treatment cancer patients. Furthermore, there is a societal need for healthcare workers to be protected and for secondary viral spread to patients to be avoided. Approaching glioblastoma patients during the COVID-19 pandemic is difficult in most neuro-oncology centers. Significant healthcare disparities between Brazilian states make it difficult for physicians to make appropriate treatment decisions. Patients with good performance status and molecular profile should receive the standard treatment protocol, including the safest resection and concurrent chemo-radiotherapy.

Older patients and those with poor performance status should be treated with caution, and a monotherapy regimen may be best suited during the COVID-19 pandemic unless patients with good performance status and no comorbidities benefit from hypofractionated protocols with temozolomide. The current situation adds new challenges to providing the best healthcare possible, and finding new ways to communicate with patients is critical. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Chemotherapy segment is expected to hold the largest market share in glioblastoma treatment market

Glioblastoma multiforme (GBM) is adults' most common primary brain tumor. No specific medications exist to treat GBM. However, certain conditions require medical treatment. For seizures, the patient usually is started on levetiracetam (Keppra), phenytoin (Dilantin), or carbamazepine (Tegretol). Levetiracetam is often used because it lacks the effects on the P450 system seen with phenytoin and carbamazepine, which can interfere with antineoplastic therapy. Chemotherapy is a common type of treatment for glioblastoma multiforme. Most patients begin chemotherapy two to four weeks after surgery, concurrently or shortly after radiation therapy. Chemotherapy is sometimes the primary treatment when a tumor cannot be surgically removed. It works by using powerful medications to destroy rapidly dividing cancer cells. These medications can be taken as pills, injected into a vein, or, in some cases, injected into the intrathecal space of the spine.

Chemotherapy for glioblastoma requires a high level of expertise because tumors are frequently made up of multiple types of cells. Some medications may kill some of these cells while allowing others to proliferate unhindered. As a result, medical oncologists must carefully tailor treatment plans for glioblastoma patients. These factors will drive the segment's growth during the forecast period. Efforts to develop new treatments have focused on discovering new drug targets and categorizing patients based on age and molecular cancer markers. Immunotherapy, RIT, or dietary treatments combined with standard radio(chemo)therapy are other promising research avenues currently in translational development. Patients undergoing chemotherapy are given drugs that are designed to kill tumor cells. The current gold standard of treatment for GBM is chemotherapy with temozolomide. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global glioblastoma treatment market

North America region accounted for the largest market share in 2021. Owing to significant market players, increasing healthcare awareness, and FDA approvals for novel drugs and the development of advanced treatment methods that counter glioma stem cells' resistive properties are also positively influencing market growth. Additionally, increasing research and development (R & R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated various biological drugs. These drugs assist in diminishing the side effects of the existing treatment methods, thus creating broader acceptance amongst patients. New drug approvals and launches for GBM treatment are expected to drive market growth in the region. For instance, in January 2020, Pfizer launched 'Zirabev' in the U.S. It is a bevacizumab biosimilar to Avastin, approved for treating recurrent glioblastoma multiforme.

Additionally, On April 09, 2021, Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM). Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the glioblastoma treatment market are Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries, Ltd., F. Hoffman-La Roche, Novartis AG and Pfizer.

On April 09, 2021, Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM).

Genentech Inc.:

Overview:

Genentech Inc. is a biotechnology company based in the United States that became a subsidiary of Roche in 2009. The company is dedicated to pioneering science to discover and develop medicines for people suffering from serious and life-threatening diseases. In the United States, Roche and Genentech merged their pharmaceutical operations. The Genentech campus in South San Francisco is now the headquarters for Roche's pharmaceutical operations in the United States. Genentech Research and Early Development is a separate entity within Roche. Roche Holding Ltd. owns 66 percent of Genentech but allows it to operate independently. Genentech discovers, develops, manufactures, and sells human pharmaceuticals to meet critical medical needs.

Product Portfolio:

Avastin (bevacizumab): Avastin (bevacizumab) is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

The global glioblastoma treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. arket Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness by educating people living with glioblastoma multiforme through various initiatives undertaken by governments and non-government bodies across the globe is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost associated with treating the glioblastoma multiforme is a major factor that hampers the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Chemotherapy*
      • 7.2.1.1. Temozolomide
      • 7.2.1.2. Introduction
      • 7.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.2.1.4. Bevacizumab
      • 7.2.1.5. Carmustine
      • 7.2.1.6. Others
  • 7.3. Immunotherapy
  • 7.4. Electric-field therapy
  • 7.5. Others

8. By Type of Molecule

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 8.1.2. Market Attractiveness Index, By Type of Molecule
  • 8.2. Small Molecules*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biologics

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Parenteral

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user
  • 10.2. Hospitals*
      • 10.2.1.1. Introduction
      • 10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Genentech*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Amgen
  • 13.3. Merck & Co., Inc
  • 13.4. Teva Pharmaceutical Industries, Ltd.
  • 13.5. Arbor Pharmaceuticals LLC
  • 13.6. Sun Pharmaceutical Industries, Ltd.
  • 13.7. F. Hoffman-La Roche
  • 13.8. Novartis AG
  • 13.9. Pfizer

LIST NOT EXHAUSTIVE

14. Global Glioblastoma Treatment Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us